The city of Oklahoma City, Oklahoma, currently has 196 active clinical trials seeking participants for Cancer research studies.
A Study to Investigate LYL797 in Adults With Solid Tumors
NCT05274451
Recruiting
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC). The first part of the study will determine the safe dose for the next part of the study, and will enroll TNBC and NSCLC patients. The second part of the study will test that dose in additional TNBC and NSCLC patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/29/2024
Locations: University of Oklahoma, Oklahoma City, Oklahoma
Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC
Register for Updates
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
NCT04278144
Recruiting
A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2024
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer, HER2-positive Endometrial Cancer
Register for Updates
First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
NCT05527184
Recruiting
IMGN151-1001 is a Phase 1, first in human, open-label dose-escalation and expansion study in adult patients with recurrent endometrial cancer, recurrent, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Register for Updates
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
NCT01492972
Recruiting
The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The benefit of the combination with androgen suppression is not completely understood. This study will compare the use of hypofraction proton therapy (28 treatments) alone to proton therapy with androgen suppression therapy.
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: Oklahoma Proton Center, Oklahoma City, Oklahoma
Conditions: Prostate Cancer
Register for Updates
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
NCT01766297
Recruiting
The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will prove to be beneficial for women with early stage breast cancer. A clinical study is necessary to compare the results (good or bad) of proton radiation therapy.
Gender:
Female
Ages:
50 years and above
Trial Updated:
02/21/2024
Locations: Oklahoma Proton Center, Oklahoma City, Oklahoma
Conditions: Breast Cancer, Breast Neoplasm, Breast Tumor, Cancer of the Breast
Register for Updates
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
NCT04831580
Recruiting
This is a randomized controlled trial to compare survival for patients who undergi robotic assisted laparoscopy versus open radical hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Cervical Cancer
Register for Updates
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
NCT05601752
Recruiting
This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4.
Gender:
Female
Ages:
Between 18 years and 75 years
Trial Updated:
02/15/2024
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Ovarian Cancer
Register for Updates
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT04044859
Recruiting
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non-small cell lung (NSCLC), ovarian or urothelial cancer.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/15/2024
Locations: OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Esophageal Cancer, Ovarian Cancer, Endometrial Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Non-small Cell Lung (NSCLC), Urothelial Cancer
Register for Updates
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
NCT05954143
Recruiting
This is an open-label, Phase 2 study to evaluate preliminary anti-tumor activity, safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of BDC-1001 administered as a single agent and in combination with pertuzumab in subjects with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (Enhertu®).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Metastatic Breast Cancer, HER2-positive Breast Cancer
Register for Updates
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
NCT05471128
Recruiting
The purpose of this study is to find out how best to detect clinically significant lesions of prostate cancer by using micro-ultrasound technology (ExactVu) and by multiparametric magnetic-resonance imaging (mpMRI).
Gender:
Male
Ages:
Between 18 years and 99 years
Trial Updated:
02/13/2024
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Prostate Cancer
Register for Updates
High Dose Omeprazole in Patients With Pancreatic Cancer
NCT04930991
Recruiting
The purpose of this study is to test the safety of high dose omeprazole and see what effects that it has on patients with exocrine pancreatic cancer.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
02/13/2024
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Exocrine Pancreatic Cancer
Register for Updates
Bariatric Education for Women With Obesity and Endometrial Cancer
NCT05396794
Recruiting
The purpose of this study is to examine whether a standardized video education tool will improve knowledge regarding obesity and bariatric surgery and increase bariatric surgery referrals for obese women with endometrial cancer.
Gender:
Female
Ages:
Between 18 years and 80 years
Trial Updated:
02/12/2024
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Obesity, Endometrial Cancer, Bariatric Surgery Candidate
Register for Updates